
John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, review the pathophysiology of psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, review the pathophysiology of psoriatic arthritis.

A panel of experts discuss the presentation of psoriatic arthritis and domains of disease.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of patient communication and the role of advanced practice clinicians.

Experts delve into considerations regarding management of comorbidities in patients with psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, discuss the common triggers patients with psoriatic arthritis and the importance of stress management.

Thought leaders discuss differences in recommendations between guidelines for the management of psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of shared decision-making in the treatment of psoriatic arthritis.

The panel explains the many conventional DMARDs that can be used to treat psoriatic arthritis, as well as their role in management.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, profile classes of interleukin inhibitors and the potential benefits for patients with psoriatic arthritis.

Three experts discuss measurement of outcomes for psoriatic arthritis management and what a “successful” treatment looks like.

A panel of experts and colleagues recall the indicators and steps that need to be taken when changing PsA therapies.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, emphasize the important of vaccination against COVID-19 for patients with psoriatic arthritis.

Three colleagues share insights into their evolving approaches regarding the management of patients with psoriatic arthritis who test positive for COVID-19.

Expert panelists share tips for boosting patient compliance among patients with psoriatic arthritis.

John Tesser, MD, closes the discussion with unmet needs in the PsA treatment landscape, as well as what he hopes to see in the future.